Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System

NCT03626896 is registered in ClinicalTrials.gov with NaviFUS Corporation as lead sponsor.

NCT NCT03626896
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03626896 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A FIH Feasibility Study to Evaluate the Safety of Transient Disruption of Blood-brain Barrier in Recurrent Glioblastoma Multiforme (GBM) Patients Using NaviFUS System
Lead sponsor
NaviFUS Corporation
Phase
Not applicable
Overall status
Completed
Start date
August 17, 2018
Completion date
June 19, 2019
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

brain tumor, glioblastoma, glioblastoma multiforme, glioma, neoplasms, neoplasms, nerve tissue